Literature DB >> 12578988

Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection.

Fadie T Coleman1, Simone Mueschenborn, Gloria Meluleni, Christopher Ray, Vincent J Carey, Sara O Vargas, Carolyn L Cannon, Frederick M Ausubel, Gerald B Pier.   

Abstract

No transgenic cystic fibrosis (CF) mouse model developed to date mimics the major clinical phenotype found in humans with CF, chronic Pseudomonas aeruginosa lung infection. In a transgenic CF transmembrane conductance regulator (cftr) mouse colony, we found WT, heterozygous, and homozygous CF mice housed in the same cage became chronically colonized in the oropharynx with environmental P. aeruginosa when the bacterium was present in drinking water. Elimination of P. aeruginosa from drinking water resulted in clearance in most WT and CF heterozygous, but not homozygous mice. For experimental evaluation, a combination of specific animal husbandry techniques and an oral infection route showed cftr(-/-) mice but not WT mice can be chronically colonized by P. aeruginosa with subsequent lung translocation, yielding a pathologic picture indicative of chronic lung infection. In some instances, mucoid isolates of P. aeruginosa were recovered from lungs, indicating conditions were present for conversion to mucoidy. Overexpression of human CFTR in the lungs of WT mice markedly accelerated the clearance rate of P. aeruginosa, demonstrating that lung levels of CFTR play an important role in defense against infection. P. aeruginosa mutants unable to express the surface polysaccharide alginate or the global regulator GacA were deficient in their ability to colonize the mice. CF mice made potent immune responses to P. aeruginosa outer membrane antigens. Overall, we found that under the proper conditions, transgenic CF mice are hypersusceptible to P. aeruginosa colonization and infection and can be used for evaluations of lung pathophysiology, bacterial virulence, and development of therapies aimed at treating CF lung disease.

Entities:  

Mesh:

Year:  2003        PMID: 12578988      PMCID: PMC149939          DOI: 10.1073/pnas.0437901100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation.

Authors:  Torsten H Schroeder; Martin M Lee; Patrick W Yacono; Carolyn L Cannon; A Alev Gerçeker; David E Golan; Gerald B Pier
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

2.  Pseudomonas aeruginosa GacA, a factor in multihost virulence, is also essential for biofilm formation.

Authors:  M D Parkins; H Ceri; D G Storey
Journal:  Mol Microbiol       Date:  2001-06       Impact factor: 3.501

3.  Quantitation and identification of antibodies to outer-membrane proteins of Pseudomonas aeruginosa in sera of patients with cystic fibrosis.

Authors:  R E Hancock; E C Mouat; D P Speert
Journal:  J Infect Dis       Date:  1984-02       Impact factor: 5.226

4.  Transgenic cystic fibrosis mice exhibit reduced early clearance of Pseudomonas aeruginosa from the respiratory tract.

Authors:  T H Schroeder; N Reiniger; G Meluleni; M Grout; F T Coleman; G B Pier
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

5.  Role of cystic fibrosis transmembrane conductance regulator in pulmonary clearance of Pseudomonas aeruginosa in vivo.

Authors:  Z C Chroneos; S E Wert; J L Livingston; D J Hassett; J A Whitsett
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

6.  Development of bronchus-associated lymphoid tissue in chronic hypersensitivity pneumonitis.

Authors:  T Suda; K Chida; H Hayakawa; S Imokawa; M Iwata; H Nakamura; A Sato
Journal:  Chest       Date:  1999-02       Impact factor: 9.410

Review 7.  CFTR mutations and host susceptibility to Pseudomonas aeruginosa lung infection.

Authors:  Gerald B Pier
Journal:  Curr Opin Microbiol       Date:  2002-02       Impact factor: 7.934

8.  Murine models of chronic Pseudomonas aeruginosa lung infection.

Authors:  Anna M van Heeckeren; M D Schluchter
Journal:  Lab Anim       Date:  2002-07       Impact factor: 2.471

9.  Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis.

Authors:  G Döring; N Høiby
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

10.  Polysaccharide surface antigens expressed by nonmucoid isolates of Pseudomonas aeruginosa from cystic fibrosis patients.

Authors:  G B Pier; D Desjardins; T Aguilar; M Barnard; D P Speert
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

View more
  40 in total

1.  Vanadate and triclosan synergistically induce alginate production by Pseudomonas aeruginosa strain PAO1.

Authors:  F Heath Damron; Michael R Davis; T Ryan Withers; Robert K Ernst; Joanna B Goldberg; Guangli Yu; Hongwei D Yu
Journal:  Mol Microbiol       Date:  2011-06-16       Impact factor: 3.501

2.  The sensor kinase KinB regulates virulence in acute Pseudomonas aeruginosa infection.

Authors:  Nikhilesh S Chand; Jenny See-Wai Lee; Anne E Clatworthy; Aaron J Golas; Roger S Smith; Deborah T Hung
Journal:  J Bacteriol       Date:  2011-04-22       Impact factor: 3.490

3.  Modification of Pseudomonas aeruginosa Pa5196 type IV Pilins at multiple sites with D-Araf by a novel GT-C family Arabinosyltransferase, TfpW.

Authors:  Julianne V Kus; John Kelly; Luc Tessier; Hanjeong Harvey; Dennis G Cvitkovitch; Lori L Burrows
Journal:  J Bacteriol       Date:  2008-09-19       Impact factor: 3.490

4.  Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model.

Authors:  Alessandra Bragonzi; Dieter Worlitzsch; Gerald B Pier; Petra Timpert; Martina Ulrich; Morten Hentzer; Jens Bo Andersen; Michael Givskov; Massimo Conese; Gerd Doring
Journal:  J Infect Dis       Date:  2005-06-24       Impact factor: 5.226

5.  Cross-sectional analysis of clinical and environmental isolates of Pseudomonas aeruginosa: biofilm formation, virulence, and genome diversity.

Authors:  Nathan E Head; Hongwei Yu
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  Analysis of acquisition of Pseudomonas aeruginosa gastrointestinal mucosal colonization and horizontal transmission in a murine model.

Authors:  Akinobu Kamei; Andrew Y Koh; Mihaela Gadjeva; Gregory P Priebe; Stephen Lory; Gerald B Pier
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

7.  Caveolin-1 modifies the immunity to Pseudomonas aeruginosa.

Authors:  Mihaela Gadjeva; Catherine Paradis-Bleau; Gregory P Priebe; Raina Fichorova; Gerald B Pier
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

8.  Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulator-modulated interleukin-1 (IL-1) release and signaling through the IL-1 receptor.

Authors:  Nina Reiniger; Martin M Lee; Fadie T Coleman; Christopher Ray; David E Golan; Gerald B Pier
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

9.  Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cftr in airway epithelia.

Authors:  David R Koehler; Umadevi Sajjan; Yu-Hua Chow; Bernard Martin; Geraldine Kent; A Keith Tanswell; Colin McKerlie; Janet F Forstner; Jim Hu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205

10.  Novel experimental Pseudomonas aeruginosa lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis.

Authors:  Claus Moser; Maria Van Gennip; Thomas Bjarnsholt; Peter Østrup Jensen; Baoleri Lee; Hans Petter Hougen; Henrik Calum; Oana Ciofu; Michael Givskov; Søren Molin; Niels Høiby
Journal:  APMIS       Date:  2009-02       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.